BioMarin Pharmaceutical

ISIN US09061G1013

WKN 924801

Market cap (in EUR)

10,003 m

Country

United States

Sector

Healthcare

Dividend yield

0.00%

Overview

Quote

Description

BioMarin Pharmaceutical, Inc. is a global rare disease biotechnology company focused on delivering medicines for people living with genetically defined conditions. The company has a proven track record of innovation, with nine commercial therapies and a strong clinical and preclinical pipeline. Using a distinctive approach to drug discovery and development, BioMarin seeks to unleash the full potential of genetic science by pursuing category-defining medicines that have a profound impact on patients. The company was founded by John C. Klock, Christopher M. Starr and Grant W. Denison on March 21, 1997 and is headquartered in San Rafael, CA.

Show more Show less

Healthcare Biopharmaceuticals System-Specific Biopharmaceuticals United States

Chart

Financials

Key metrics

Market capitalisation, EUR	10,003 m
EPS, EUR	1.18
P/B ratio	1.8
P/E ratio	43.1
Dividend yield	0.00%

Income statement (2025)

Revenue, EUR	2,874 m
Net income, EUR	309 m
Profit margin	10.76%

What ETF is BioMarin Pharmaceutical in?

There are 15 ETFs which contain BioMarin Pharmaceutical. All of these ETFs are listed in the table below. The ETF with the largest weighting of BioMarin Pharmaceutical is the iShares Nasdaq US Biotechnology UCITS ETF USD (Dist).

ETF	Weight	Investment focus	Fund size (in m EUR)
Vanguard LifeStrategy 80% Equity UCITS ETF (EUR) Accumulating	0.02%	Equity World Multi-Asset Strategy	1,183
Vanguard LifeStrategy 20% Equity UCITS ETF Distributing	0.01%	Equity World Multi-Asset Strategy	16
Vanguard LifeStrategy 80% Equity UCITS ETF Distributing	0.02%	Equity World Multi-Asset Strategy	90
Vanguard LifeStrategy 60% Equity UCITS ETF Accumulating	0.01%	Equity World Multi-Asset Strategy	903
Vanguard LifeStrategy 40% Equity UCITS ETF Accumulating	0.01%	Equity World Multi-Asset Strategy	235
Vanguard ESG Global All Cap UCITS ETF (USD) Distributing	0.01%	Equity World Social/Environmental	600
JPMorgan BetaBuilders US Small Cap Equity UCITS ETF USD (dist)	0.15%	Equity United States Small Cap	225
iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)	0.88%	Equity United States Health Care Biotech	64
JPMorgan US Equity Premium Income Active UCITS ETF EUR (dist)	0.01%	Equity United States Covered Call Alternative Investments	42
Vanguard ESG North America All Cap UCITS ETF (USD) Distributing	0.02%	Equity North America Social/Environmental	27
JPMorgan US Equity Premium Income Active UCITS ETF EUR Hedged (dist)	0.01%	Equity United States Covered Call Alternative Investments	17
JPMorgan US Equity Premium Income Active UCITS ETF USD (dist)	0.01%	Equity United States Covered Call Alternative Investments	370
Vanguard LifeStrategy 60% Equity UCITS ETF Distributing	0.01%	Equity World Multi-Asset Strategy	117
Vanguard LifeStrategy 40% Equity UCITS ETF Distributing	0.01%	Equity World Multi-Asset Strategy	43
Vanguard LifeStrategy 20% Equity UCITS ETF Accumulating	0.01%	Equity World Multi-Asset Strategy	100

Performance

Returns overview

YTD	+2.00%
1 month	+7.18%
3 months	+11.01%
6 months	+9.49%
1 year	+4.49%
3 years	-31.88%
5 years	-25.06%
Since inception (MAX)	-38.38%
2025	-19.79%
2024	-27.75%
2023	-8.14%
2022	+20.96%

Monthly returns in a heat map

Risk

Risk metrics in this section:

Volatility, annualised, measured for 1, 3 and 5 year periods. The annualised volatility reflects the degree of price fluctuations during a one year period. The higher the volatility, the more significantly the price of the asset (stock, ETF, etc.) has changed in the past. Assets with higher volatility are generally considered more risky. We calculate the volatility based on the data for the past 1, 3 and 5 years so that you can see if price fluctuations for the ETF became stronger or weaker over time.
Return per risk for 1, 3 and 5 year periods. This is the annualised (i.e. converted to a one year period) past return divided by the past annualised volatility. The metric puts the historical return of an asset in relation to its historical risk and gives you a retrospective indication of the degree of price fluctuation you had to bear with in order to obtain the return. We calculate this parameter for 1, 3 and 5 year periods to display its evolution over time.
Maximum drawdown for a period. This shows the worst possible loss an investor could have suffered during the respective period, by first buying and subsequently selling the asset at the least favourable prices. For example, if there was the following sequence of daily ETF prices: 10€, 5€, 12€, 20€, an investor would have suffered the worst loss by buying for 10€ and subsequently selling for 5€. Therefore in this case the maximum drawdown would be (5€ - 10€)/10€ = -50%.

ETF returns include dividend payments (if applicable).